prikaz prve stranice dokumenta Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
Access restricted to students and staff of home institution
Scientific paper - Preliminary note / Short communication
Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
Digestive and Liver Disease, 50 (2018), 12; 1362-1365. https://doi.org/10.1016/j.dld.2018.07.042
(STARK Project - Pancreas 2000 Program) Korpela, Taija; Cárdenas-Jaén, Karina; Archibugi, Livia; Poropat, Goran; Maisonneuve, Patrick; Arcidiacono, Paolo Giorgio; De Pretis, Niccolò; Löhr, Matthias; Capurso, Gabriele; de-Madaria, Enrique

Cite this document

Korpela, T., Cárdenas Jaén, K., Archibugi, L., Poropat, G., Maisonneuve, P., Arcidiacono, P. G. ... de Madaria, E. (2018). Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study. Digestive and Liver Disease, 50. (12), 1362-1365. doi: 10.1016/j.dld.2018.07.042

Korpela, Taija, et al. "Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study." Digestive and Liver Disease, vol. 50, no. 12, 2018, pp. 1362-1365. https://doi.org/10.1016/j.dld.2018.07.042

Korpela, Taija, Karina Cárdenas Jaén, Livia Archibugi, Goran Poropat, Patrick Maisonneuve, Paolo Giorgio Arcidiacono, Niccolò De Pretis, Matthias Löhr, Gabriele Capurso and Enrique de Madaria. "Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study." Digestive and Liver Disease 50, no. 12 (2018): 1362-1365. https://doi.org/10.1016/j.dld.2018.07.042

Korpela, T., et al. (2018) 'Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study', Digestive and Liver Disease, 50(12), pp. 1362-1365. doi: 10.1016/j.dld.2018.07.042

Korpela T, Cárdenas Jaén K, Archibugi L, Poropat G, Maisonneuve P, Arcidiacono PG, and sur.. Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study. Digestive and Liver Disease [Internet]. 2018 December [cited 2024 June 25];50(12):1362-1365. doi: 10.1016/j.dld.2018.07.042

T. Korpela, et al., "Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study", Digestive and Liver Disease, vol. 50, no. 12, pp. 1362-1365, December 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:661675. [Accessed: 25 June 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Chronic use of statins and risk of post-ERCP acute pancreatitis (STARK): Study protocol for an international multicenter prospective cohort study
AuthorTaija Korpela
AuthorKarina Cárdenas-Jaén
AuthorLivia Archibugi
AuthorGoran Poropat
AuthorPatrick Maisonneuve
AuthorPaolo Giorgio Arcidiacono
AuthorNiccolò De Pretis
AuthorMatthias Löhr
AuthorGabriele Capurso
AuthorEnrique de-Madaria
CollaborationSTARK Project - Pancreas 2000 Program
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Acute pancreatitis (AP) is the most common complication after endoscopic retrograde cholangiopancreatography (ERCP). Statins have been traditionally associated to an increased risk of AP, however, recent evidence suggests that statins may have a protective role against this disease. Aims: Our primary aim is to investigate whether the use of statins has a protective effect against post-ERCP pancreatitis (PEP). Secondary outcomes are: to evaluate the effect of other drugs on the incidence of PEP; to ascertain the relationship between the use of statins and the severity of PEP; and to evaluate the effect of other risk and protective factors on the incidence of PEP. Methods: STARK is an international multicenter prospective cohort study. Centers from Spain, Italy, Croatia, Finland and Sweden joined this study. The total sample size will include about 1016 patients, which was based on assuming a 5% incidence of PEP among non-statin (NSt) users, a 1-3 ratio of statin (St) and NSt consumers respectively, a 70% decrease in PEP among St consumers, an alpha-error of 0.05 and beta-error of 0.20. All patients aged ≥18 years scheduled for ERCP will be offered to enter the study. Discussion: STARK study will ascertain whether statins, a safe, widely used and inexpensive drug, can modify the incidence of PEP.
Keywords (english)
Languageenglish
Publication typeScientific paper - Preliminary note / Short communication
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleDigestive and Liver Disease
Numberingvol. 50, no. 12, pp. 1362-1365
p-ISSN1590-8658
DOIhttps://doi.org/10.1016/j.dld.2018.07.042
URN:NBNurn:nbn:hr:184:661675
Publication2018-12
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S159086581830879X
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2022-02-11 12:17:03